TRAJ3: A Potential Drug Target and Biomarker (G28752)

Target Name: TRAJ3

NCBI ID: G28752

TRAJ3

Other Name(s): T cell receptor alpha joining 3

TRAJ3: A Potential Drug Target and Biomarker

T cell receptor alpha joining 3 (TRAJ3) is a protein that is expressed in the T cells, a type of white blood cell that plays a crucial role in the immune system. T cells are responsible for recognizing and responding to foreign substances in the body, such as viruses and bacteria. When a T cell encounters a foreign substance, it becomes activated and begins to divide and differentiate into a specialized type of cell called a T cell memory cell. These memory cells are responsible for remember the encounter with the foreign substance and can differentiate into different types of T cells.

TRAJ3 is a protein that is expressed in T cells and is involved in the process of T cell activation and differentiation. It is a member of the T cell receptor alpha joining 3 family, which is a group of proteins that are involved in the process of cell signaling. This family of proteins includes several different proteins, including T cell receptor alpha joining 1 (TCR伪J1), T cell receptor alpha joining 2 (TCR伪J2), and T cell receptor alpha joining 4 (TCR伪J4).

One of the functions of T cell receptor alpha joining 3 is to regulate the process of T cell activation and differentiation. This protein helps to ensure that T cells are activated and differentiate into memory cells, which are specialized cells that are responsible for storing the memory of the T cell's previous encounters with foreign substances.

TRAJ3 is also involved in the regulation of the immune response. This protein helps to coordinate the activities of different immune cells, including T cells, B cells, and natural killer cells. It also helps to regulate the production of antibodies, which are proteins that are responsible for neutralizing foreign substances in the body.

TRAJ3 is a protein that is being targeted as a potential drug target for several different diseases. One of the main reasons for its potential as a drug target is its involvement in the immune system. Trajectin 3 has been shown to play a role in the regulation of the immune response, and it is thought to be involved in the development of autoimmune diseases.

In addition to its potential as a drug target, TRAJ3 is also being studied as a potential biomarker. This is because its levels can be easily measured and are not affected by factors such as age or gender. This makes it an attractive candidate for use as a biomarker in clinical trials.

Overall, T cell receptor alpha joining 3 (TRAJ3) is a protein that is involved in the process of T cell activation and differentiation, and it is being targeted as a potential drug target and biomarker. Further research is needed to fully understand its role in the immune system and its potential as a therapeutic agent.

Protein Name: T Cell Receptor Alpha Joining 3

Functions: J region of the variable domain of T cell receptor (TR) alpha chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRAJ3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAJ3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets